CNTX
Context Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. up to 70% of breast cancers express progesterone receptor (pr). if your cancer is pr+, apristor could be an option for you.
Market Cap: 16.8 Million
Primary Exchange: NASDAQ
Website: http://www.contexttherapeutics.com/
Shares Outstanding: 16 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.1299679248469434
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 758 trading days
From: 2021-10-25 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|